Core Viewpoint - Tevogen Bio Holdings Inc. has signed a non-exclusive, non-binding Letter of Intent to evaluate a potential acquisition of Sciometrix Inc., which would lead to Tevogen holding a majority voting interest in Sciometrix if completed [1][2]. Group 1: Potential Transaction - The transaction aims to enhance Tevogen's capabilities and transition it into a revenue-generating healthcare enterprise by integrating Sciometrix's digital care management platform, Clinicus, and remote patient monitoring technologies with Tevogen.AI [2][11]. - Sciometrix has achieved significant milestones, becoming one of the top 25 digital healthcare companies in the USA, and aims to break into the top 10 with the integration of Tevogen.AI [2]. - The proposed transaction is subject to due diligence, negotiation, execution of definitive documentation, required approvals, and customary closing conditions [2]. Group 2: Company Background - Tevogen is a healthcare enterprise focused on affordability, efficiency, and scientific rigor, leveraging AI and precision T cell therapy platforms to develop advanced therapies across multiple areas [4]. - Tevogen Bio has completed a proof-of-concept clinical trial for its T cell therapy, with a pipeline that includes virology, oncology, and neurology [5]. - Tevogen.AI aims to transform drug development by improving target detection and clinical trial design through predictive technologies [6]. Group 3: Future Initiatives - Tevogen is exploring additional strategic initiatives in life sciences, including domestic generics, biosimilars, medical devices, and innovative insurance solutions [3][7].

Core Viewpoint - Tevogen Bio Holdings Inc. has signed a non-exclusive, non-binding Letter of Intent to evaluate a potential acquisition of Sciometrix Inc., which would lead to Tevogen holding a majority voting interest in Sciometrix if completed [1][2]. Group 1: Potential Transaction - The transaction aims to enhance Tevogen's capabilities and transition it into a revenue-generating healthcare enterprise by integrating Sciometrix's digital care management platform, Clinicus, and remote patient monitoring technologies with Tevogen.AI [2][11]. - Sciometrix has achieved significant milestones, becoming one of the top 25 digital healthcare companies in the USA, and aims to break into the top 10 with the addition of Tevogen.AI's capabilities [2]. - The proposed transaction is subject to due diligence, negotiation, execution of definitive documentation, required approvals, and customary closing conditions [2]. Group 2: Company Profiles - Tevogen is focused on creating a socially integrated healthcare enterprise that emphasizes affordability, efficiency, and scientific rigor, leveraging AI and precision T cell therapy platforms [4]. - Sciometrix provides enterprise care management, digital patient engagement, predictive analytics, and value-based care solutions to healthcare organizations across the nation [8]. Group 3: Strategic Initiatives - Tevogen is exploring additional strategic initiatives in life sciences, including domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers [3][7]. - The integration of Clinicus is expected to accelerate Tevogen's commercialization readiness by aligning clinical development with real-world patient engagement and outcomes tracking [11].